1. Home
  2. VYGR vs WLII Comparison

VYGR vs WLII Comparison

Compare VYGR & WLII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$3.23

Market Cap

203.6M

Sector

Health Care

ML Signal

HOLD

WLII

Willow Lane Acquisition Corp. II Class A Ordinary Shares

N/A

Current Price

$10.26

Market Cap

205.1M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
VYGR
WLII
Founded
2013
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
203.6M
205.1M
IPO Year
2015
2026

Fundamental Metrics

Financial Performance
Metric
VYGR
WLII
Price
$3.23
$10.26
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$16.50
N/A
AVG Volume (30 Days)
504.7K
96.4K
Earning Date
05-08-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,135,000.00
N/A
Revenue This Year
$34.04
N/A
Revenue Next Year
$7.92
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.94
$10.16
52 Week High
$5.55
$10.29

Technical Indicators

Market Signals
Indicator
VYGR
WLII
Relative Strength Index (RSI) 50.52 60.67
Support Level $2.95 $10.23
Resistance Level $3.30 $10.29
Average True Range (ATR) 0.14 0.02
MACD 0.04 -0.00
Stochastic Oscillator 75.95 51.85

Price Performance

Historical Comparison
VYGR
WLII

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.

About WLII Willow Lane Acquisition Corp. II Class A Ordinary Shares

Willow Lane Acquisition Corp II is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Share on Social Networks: